InvestSMART

Equatorial Resources Limited (ASX: EQX) - Announcements

- Current share price for EQX : $0.160

ASX company news and announcements for Equatorial Resources Limited (EQX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Equatorial Resources Limited (EQX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Equatorial Resources Limited (EQX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Equatorial Resources Limited (EQX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$21 Invests Further $0.5M in VacTX Vaccine Project 30 Jan 2006 10:30AM n/a $0.160 n/a
$21 Commitments Test Entity - First Quarter Report 28 Oct 2005 3:25PM n/a $0.160 n/a
$21 Preliminary Final Report 13 Sep 2005 10:47AM $0.200 $0.160 fallen by 20%
$21 $1.45M Grant Awarded for Pain Relief Drug Candidate 30 Aug 2005 11:18AM $0.260 $0.160 fallen by 38.46%
$21 Invests further $0.5 in VacTX Vaccine Project 3 Aug 2005 10:46AM $0.285 $0.160 fallen by 43.86%
$21 Commitments Test Entity - Fourth Quarter Report 29 Jul 2005 12:12PM $0.260 $0.160 fallen by 38.46%
$21 Increases Equity in ZingoTX Pain Treatment Company to 54% 28 Jul 2005 10:25AM $0.250 $0.160 fallen by 36%
$21 Enters research collaboration with Johns Hopkins University 30 May 2005 10:22AM $0.250 $0.160 fallen by 36%
$21 TGA approves Clinical Trial using Immune Technology 25 May 2005 10:21AM $0.240 $0.160 fallen by 33.33%
$21 Gains Controlling Stake in Zingo TX 4 Apr 2005 10:57AM n/a $0.160 n/a
$21 Increases its equity in VacTX with add $0.5m investment 24 Jan 2005 12:14PM $0.280 $0.160 fallen by 42.86%
$21 To raise $1.8m 7 Dec 2004 10:15AM $0.300 $0.160 fallen by 46.67%
$21 Fourth Quarter Activities Report 30 Jul 2004 10:59AM n/a $0.160 n/a
$21 US Patent granted for VacTX vaccine technology 16 Mar 2004 12:35PM $0.380 $0.160 fallen by 57.89%
$21 Half Yearly Report 24 Feb 2004 7:58PM $0.420 $0.160 fallen by 61.90%
$21 Potential New Pain/Inflammation Drugs Advance to Milestone 2 11 Feb 2004 10:18AM $0.375 $0.160 fallen by 57.33%
$21 Co-Op Res Ctr for Vaccine Tech & EQX ann new dev venture 20 Jan 2004 2:12PM $0.440 $0.160 fallen by 63.64%
$21 Co-Op Res Ctr for Vaccine Tech & EQX ann new dev venture 20 Jan 2004 2:12PM $0.440 $0.160 fallen by 63.64%
$21 Acquires New Vaccine Technology for $3.5M 20 Jan 2004 10:04AM $0.440 $0.160 fallen by 63.64%
$21 Acquires New Vaccine Technology for $3.5M 20 Jan 2004 10:04AM $0.440 $0.160 fallen by 63.64%
$21 Agrees Terms for new vaccine technology 14 Nov 2003 10:11AM $0.430 $0.160 fallen by 62.79%
$21 Raises $2.7 Million 1 Oct 2003 10:52AM $0.330 $0.160 fallen by 51.52%
$21 Preliminary Final Report 12 Sep 2003 1:20PM $0.310 $0.160 fallen by 48.39%
$21 Granted exclusive rights to negotiate acq of new vaccine tec 10 Jul 2003 11:06AM $0.245 $0.160 fallen by 34.69%
$21 US Patent Granted for Gingerol Technology 7 Jul 2003 9:07AM $0.235 $0.160 fallen by 31.91%

326 - 350 of 351 results

Page 14 of 15

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.